Cargando…
An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability
To achieve the very high oncoprotein levels required to drive the malignant state cancer cells utilise the ubiquitin proteasome system to upregulate transcription factor levels. Here our analyses identify ALYREF, expressed from the most common genetic copy number variation in neuroblastoma, chromoso...
Autores principales: | Nagy, Zsuzsanna, Seneviratne, Janith A., Kanikevich, Maxwell, Chang, William, Mayoh, Chelsea, Venkat, Pooja, Du, Yanhua, Jiang, Cizhong, Salib, Alice, Koach, Jessica, Carter, Daniel R., Mittra, Rituparna, Liu, Tao, Parker, Michael W., Cheung, Belamy B., Marshall, Glenn M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994381/ https://www.ncbi.nlm.nih.gov/pubmed/33767157 http://dx.doi.org/10.1038/s41467-021-22143-x |
Ejemplares similares
-
A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma
por: Cheung, Belamy B., et al.
Publicado: (2021) -
Increase in DNA Damage by MYCN Knockdown Through Regulating Nucleosome Organization and Chromatin State in Neuroblastoma
por: Hu, Xinjie, et al.
Publicado: (2019) -
Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface
por: Massudi, Hassina, et al.
Publicado: (2023) -
MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation
por: Beckers, Anneleen, et al.
Publicado: (2014) -
Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)